Trastuzumab and chemotherapeutics: Drug interactions and synergies

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 11, 2000, Pages 21-25

  Pegram, M D ^a   Lopez, A ^a   Konecny, G ^a   Slamon, D J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; THIOTEPA; TRASTUZUMAB; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG CYTOTOXICITY; DRUG POTENTIATION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENES, ERBB-2; HUMANS; TUMOR CELLS, CULTURED;

EID: 0034473393     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
2. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
3. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
4. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
5. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
6. Qualitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
7. A model-based approach for assessing in vivo combination therapy interactions
8. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
9. Overall survival (OS) advantage to simultaneous chemotherapy (Crx) plus the humanized anti-HER2 monoclonal antibody trastuzumab (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
10. Herceptin and vinorelbine for HER-2-positive metastatic breast cancer: A phase II study
11. Addition of trastuzumab (humanized anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial